Objective To investigate the possible interaction between the ras and p53 genes overexpression in thyroid carcinoma, and whether there is correlation between the ras and p53 overexpression and clinico-pathological criteria.
Methods Thyroid lesions from eighty patients were examined for expression of ras and p53 genes by the LSAB immunohistochemistic method. Of these patients, 54 were diagnosed as malignant lesions and 26 benign nodular thyroid disorders.
Results The positive immunostain rate for ras and p53 genes was 90.7%, 23.0% and 55.5%, 30.7% in carcinoma and benign lesions respectively with statistically significance between thyroid carcinomas and benign disorders (Ｐ＜0.05). Both ras and p53 overexpressions coexisted in 30 thyroid carcinomas and follow-up showed that 3 of them died and 5 of them had recurrence within 4 years.
Conclusion Activation of ras gene and inactivation of p53 gene are cooperatively associated in thyroid tumorigenesis. The concurrent overexpression of ras and p53 could result in a poor prognosis.
Citation：
LI Xiaoxi,WANG Shenming,ZHAO Guohua,et al.. EXPRESSION OF ras AND p53 IN HUMAN THYROID CARCINOMA. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2000, 7(5): 299-301. doi:
Copy
Copyright © the editorial department of CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY of West China Medical Publisher. All rights reserved
| 1. |
Clark OH, Duh QY. Thyroid carcinoma 〔Ｊ〕. Med Clin North Am, 1991; 75(1)∶211.
|
| 2. |
Bishop JM. Nolecular themes in oncogenesis 〔Ｊ〕. Cell, 1991; 64(2)∶235.
|
| 3. |
Leight GSJ. Nodular goiter and benign and malignant neoplasms of the thyroid. In: Sabiston SC Jr. (Ed): Textbook of surgery 〔M〕. 14th ed. Philadelphia: WB Saunders Company, 1991∶585.
|
| 4. |
Pilotti S, Collini P, Del Bo R, et al. A novel panel of antibodies that segregates immunocytochemically poorly differentiated carcinoma undifferentiated carcinoma of the thyroid gland 〔Ｊ〕. Am J Surg Pathol, 1994; 18(10)∶1045.
|
| 5. |
Namba H, Guaman RA, Matsuo K, et al. Hras protooncogene mutations in human thyroid neoplasmas 〔Ｊ〕. J Clin Endocrinol Metab, 1990; 71(1)∶223.
|
| 6. |
Dobashi Y, Sakaomoto A, Sugimura H, et al. Overexpression of p53 as a possible prognostic factor in human thyroid carcinoma 〔Ｊ〕. Am J Surg Pathol, 1993; 17(4)∶375.
|
| 7. |
Salvatore D, Celetti A, Fabien N, et al. Low frequency of p53 mutations in human thyroid tumors: p53 and ras mutation in two out of fiftysix thyroid tumors 〔Ｊ〕. Eur J Endocrol, 1996; 134(2)∶177.
|
| 8. |
Sturm PDJ, Hruban RH, Ramsoekh TB, et al. The potential diagnostic use of Kras codon 12 and p53 altertions brush cytology from the pancreatic head regionc 〔Ｊ〕. J Pathol, 1998; 186(3)∶247.
|
- 1. Clark OH, Duh QY. Thyroid carcinoma 〔Ｊ〕. Med Clin North Am, 1991; 75(1)∶211.
- 2. Bishop JM. Nolecular themes in oncogenesis 〔Ｊ〕. Cell, 1991; 64(2)∶235.
- 3. Leight GSJ. Nodular goiter and benign and malignant neoplasms of the thyroid. In: Sabiston SC Jr. (Ed): Textbook of surgery 〔M〕. 14th ed. Philadelphia: WB Saunders Company, 1991∶585.
- 4. Pilotti S, Collini P, Del Bo R, et al. A novel panel of antibodies that segregates immunocytochemically poorly differentiated carcinoma undifferentiated carcinoma of the thyroid gland 〔Ｊ〕. Am J Surg Pathol, 1994; 18(10)∶1045.
- 5. Namba H, Guaman RA, Matsuo K, et al. Hras protooncogene mutations in human thyroid neoplasmas 〔Ｊ〕. J Clin Endocrinol Metab, 1990; 71(1)∶223.
- 6. Dobashi Y, Sakaomoto A, Sugimura H, et al. Overexpression of p53 as a possible prognostic factor in human thyroid carcinoma 〔Ｊ〕. Am J Surg Pathol, 1993; 17(4)∶375.
- 7. Salvatore D, Celetti A, Fabien N, et al. Low frequency of p53 mutations in human thyroid tumors: p53 and ras mutation in two out of fiftysix thyroid tumors 〔Ｊ〕. Eur J Endocrol, 1996; 134(2)∶177.
- 8. Sturm PDJ, Hruban RH, Ramsoekh TB, et al. The potential diagnostic use of Kras codon 12 and p53 altertions brush cytology from the pancreatic head regionc 〔Ｊ〕. J Pathol, 1998; 186(3)∶247.
